pharma news today glp-1 Lilly is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating GLP-1 agonist clinical pipeline 2026:

The knockout findings indicate a more complex relationship involving chronic receptor-associated adaptation and beta-3-independent acute effects

only 6% of women and 11% of men had dietary intakes greater than the AI (105)

The September 2024 LIFT-AD trial termination after meeting enrollment demonstrates that this approach, despite decades of development, does not slow Alzheimer's cognitive decline in humans

Studies have shown complex interactions between GHK-Cu and MMP-2, with effects that vary by concentration and cellular context

Odermatt A

At the cellular level, GLP-1RAs provide liver protection through three main pathways: reprogramming Kupffer cells to reduce inflammation, resetting metabolism via FXR/LXR-mediated lipid efflux, and directly promoting hepatocyte survival through the PI3K/Akt pathway